CBD Inhibition of CYP2C9 CSV JSON

Natural product: Cannabis (Cannabis sativa)
Associated study: Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

In Vitro Enzyme Inhibition Experiment

CBD Inhibition of CYP2C9

Inhibition was detected. Cutoff used —
CBD was predicted to precipitate strong drug interactions (AUCR greater than or equal to 5) mediated by CYP2C9, 2C19, and 3A and moderate drug interactions (AUCR between 1.2 and 5) mediated by CYP1A2 and 2D6 based on the AUCR cutoffs recommended by the FDA (https://www.fda.gov/media/134582/ download).

Object compound

diclofenac 1124300

Precipitant

Object metabolite investigated

4'-hydroxydiclofenac

Enzymes involved in metabolite pathway

CYP2C9 4309227

Test system used

Cell fraction Pooled human liver microsomes -7999662

Results

Sample	Compound measured	Value	Measurement	Study sequence	Additional information	N replicates

Experimental Conditions

Protein concentration

0.1 mg/ml

Test system preparation

Commercially available

Object concentrations tested

5 µM